Financial Statements for the year ending 30 June 2021
Released
Released
Announcement PDF
Biome Australia Limited and
Controlled Entities
ABN 51 627 364 014
Financial Statements
For the Year Ended 30 June 2021
Biome Australia Limited and Controlled Entities
ABN 51 627 364 014
Contents
For the Year Ended 30 June 2021
Page
Financial Statements
Directors' Report
Auditor's Independence Declaration under Section 307C of the Corporations Act 2001
Statement of Profit or Loss and Other Comprehensive Income
Statement of Financial Position
Statement of Changes in Equity
Statement of Cash Flows
Notes to the Financial Statements
Directors' Declaration
Independent Audit Report
1
6
7
8
9
11
12
38
39
Biome Australia Limited and Controlled Entities
ABN 51 627 364 014
Directors' Report
30 June 2021
The directors present their report, together with the financial statements of the Group, being the Company and its controlled
entities, for the financial year ended 30 June 2021.
Directors
The names of the directors in office at any time during, or since the end of, the year are:
Dr Jaroslav Haman Boublik
Douglas Chee Yong Loh
Blair William Brabin Vega Norfolk
Ilario Thomas Faenza
Dominque Fisher
Rodney William Unsworth
Michael Sven Ola Oredsson
(appointed 18 August 2020)
(appointed 12 August 2021)
(resigned 14 December 2020)
(resigned 17 December 2020)
Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.
Principal activities
The principal activities of the Group during the financial year were researching, developing, manufacturing and distributing
innovative evidence-based products linking the gut and human health through the Group owned brands:
Activated Nutrients ®, a range of completely organic, plant-based, all-in-one nutritional products;
Activated Probiotics ®, a first-of-its-kind range of clinically-backed precision probiotics; and
AXP TM, certified range of performance products for athletes.
The Group distributes its products through two channels in Australia, community pharmacies and independent health
practitioners. In international markets the Group distributes and markets its Activated Probiotics range in the United
Kingdom and New Zealand through independent health practitioners.
During the year, the Group finalised Clinical trial agreements on two of its products. The first trail, being conducted in
collaboration with La Trobe University is on sub-threshold depression, using Biome Lift ProbioticTM. This clinical trial is
currently in participant recruitment phase. The second clinical trial to be conducted in collaboration with Federation
University will be on children’s immune health. This trial is expected to commence in early calendar 2022.
A mass marketing campaign has been implemented in FY22 to support the growth of brand and sales revenue this financial
year. This includes national TV advertising campaigns, magazines and outdoor advertising.
Apart from the matters noted below under "significant changes in state of affairs", there was no significant change in the
nature of these activities occurred during the year.
Operating results
The consolidated loss of the Group amounted to $ 5,381,116 (2020: $3,162,163).
The results reflect the ongoing significant investment in developing and establishing the brand and product recognition of
the business in that financial year. In a very difficult period with Covid being a significant factor in the business environment,
the Group still achieved a healthy increase in Sales Revenue (more than 168%). Through the difficult period, the business
continued its strategy of increasing brand recognition and capturing further market share which was only possible by
1
Biome Australia Limited and Controlled Entities
ABN 51 627 364 014
Directors' Report
30 June 2021
Operating results (continued)
collaborating with staff and management, which resulted in the establishment of the employee share plan. Ongoing support
from existing shareholders enabled the Group to continue its operations to achieve the reported results.
The Group also identified and consolidated its growth in the new channel of the practitioner markets. It has further grown its
customer base and distribution networks through the engagement for several key customers. During the year, the Group
made it first overseas sales to wholesale distributors in the UK and New Zealand. The Group continues to grow and work
with its international partners to further expand the brand and product recognition internationally. For the year ended 30
June 2021, overseas sales accounted for 11% of total sales.
The Group's continued investment into its development of products has also seen the launch of two new Activated
Probiotics and two new Activated Nutrients products.
Significant changes in state of affairs
There were no significant changes in the state of affairs of entities in the Group during the year. The Group raised additional
capital as required and adapted to unprecedented business environmental factors whilst continuing to grow the business
through its core strategy.
Matters or circumstances arising after the end of the year
Subsequent to year end, the group issued 10,768,959 performance rights subject to shareholder's approval.
Dominique Fisher was appointed non-executive director as at 12 August 2021.
The group completed its pre-IPO funding, with the final applications for $1.7m of its pre-IPO raising completed this month.
It signed an agreement with Canaccord Genuity Australia to be the Lead Manager for the ASX listing of the Group,
expected by the end of November 2021.
The launch of a strategic distribution partnership with one of the largest pharmacy banner Groups in Australia continues to
translate into sales growth. The Company is confident of doubling sales for the quarter ended September 2021, compared
to the same period in 2020.
Apart from this, no other matters or circumstances have arisen since the end of the financial year which significantly
affected or could significantly affect the operations of the Group, the results of those operations or the state of affairs of the
Group in future financial years.
Future developments and results
Likely developments in the operations of the Group and the expected results of those operations in future financial years
have not been included in this report as the inclusion of such information is likely to result in unreasonable prejudice to the
Group.
Environmental matters
The Group's operations are not regulated by any significant environmental regulations under a law of the Commonwealth or
of a state or territory.
Dividends paid or recommended
No dividends were paid or declared since the start of the financial year. No recommendation for payment of dividends has
been made.
2
Biome Australia Limited and Controlled Entities
ABN 51 627 364 014
Directors' Report
30 June 2021
Information on directors
Dr Jaroslav Haman Boublik
Director, Chief Science Advisor
Consultant to the nutritional R&D sector and researcher with over 30
years of experience in nutritional and complementary medicine. Dr.
JB is Chief Scientist of LeafCann Group Pty Ltd and CEO of
LeafCann Group Research & Advisory. He has published multiple
peer-reviewed scientific articles.
Douglas Chee Yong Loh
Director, Finance
Over 30 years of advisory, accounting and finance, company
management and investment management experience. 19 years as
founding member of Acorn Capital and held positions as Portfolio
Manager, Head of Equities, CFO, COO and Director. Douglas was
Chairman of DXN Limited, an ASX listed pre-fabricated modular data
centre manufacturer, builder and operator.
Corporate secretary until 27 January 2021
Special Responsibilities
Blair William Brabin Vega Norfolk
Director, Founder and MD
Over 12 years of global pharmaceutical and FMCG experience as
management and executive. Since founding the business in 2013,
Blair has recruited the people, secured funding, products and IP and
managed key relationships. Blair has strong relationships in media,
pharmacy and manufacturing. Blair has a significant public profile as
a health advocate and speaks at conferences and panels from
Mental health to general wellbeing.
Ilario Thomas Faenza
Chairman
M&A, PE & investment banking specialist with over 30 years
experience in a range of high growth industries. Ilario has
successfully started multiple companies and provided advisory,
specialist M&A, due diligence, structuring and fund raising assistance
to numerous businesses. Ilario has raised > $100M over the past 15
years for high growth companies and actively assists management
with execution of strategy, commercial negotiations, IPO’s and exit
strategies.
Dominque Fisher
Non Executive Director
Ms Fisher couples her experience in tech driven businesses with a
strong focus on risk mitigation and financial management which has
led to her working in across a wide range of sectors in both executive
and non executive roles. Ms Fisher has an extensive non-executive
career, having served on ASX listed companies, IAG, Circadian
Technologies/ Opthea , Pacific Brands and Trimantium GrowthOps (2
as Chair) including two IPOs (IAG and TGO); numerous private
companies including Integrity Life Group, various government and
private advisory boards at both state and federal for both major
political parties, Geoscape Australia and government agencies
including the Sydney Opera House , Australia Post and the Australian
Council for the Arts
3
Biome Australia Limited and Controlled Entities
ABN 51 627 364 014
Directors' Report
30 June 2021
Company secretary
George Lazarou
George Lazarou held the position of Company secretary from 27 January 2021. He is a qualified Chartered Accountant with
over 25 years’ experience, including five years as a partner of a mid-tier accounting firm, specialising in the areas of
advisory and corporate services. Mr Lazarou has extensive skills in the areas of corporate services, due diligence,
independent expert reports, mergers & acquisitions and valuations.
Mr Lazarou has been Chairman, Non-Executive Director and Company Secretary of a number of ASX listed companies
since 2006.
Meetings of directors
During the financial year, 20 meetings of directors (including committees of directors) were held. Attendances by each
director during the year were as follows:
Directors'
Meetings
Audit Committee
Remuneration
Committee
Number
Number
Number
eligible to Number eligible to Number eligible to Number
attend
attended
attend
attended
attend
attended
Dr Jaroslav Haman Boublik
16
16
2
2
2
2
Douglas Chee Yong Loh
16
16
2
2
-
-
Blair William Brabin Vega Norfolk
16
16
-
-
-
-
Rodney William Unsworth
7
6
1
1
1
1
Michael Sven Ola Oredsson
7
6
-
-
-
-
Ilario Thomas Faenza
13
12
1
1
2
2
Options
Unissued shares under option
At the date of this report, the unissued ordinary shares of Biome Australia Limited and Controlled Entities under option are
as follows:
Grant Date
01 September 2020
08 February 2019
08 February 2019
Date of Expiry
31 October 2021
30 June 2022
30 June 2023
Exercise Price
$0.10
$0.09
$0.12
Number under Option
21,045,450
4,500,000
4,500,000
30,045,450
No issue right for option holders
Option holders do not have any rights to participate in any issues of shares or other interests in the Company or a
controlled entity.
4
Biome Australia Limited and Controlled Entities
ABN 51 627 364 014
Directors' Report
30 June 2021
Indemnification and insurance of officers and auditors
The officers of Biome Australia Limited are indemnified by the Company. Every officer of the Company shall be indemnified
out of the property of the Company against any liability incurred by him in his capacity as officer in defending any
proceedings in which judgement is given in his favour or in which he is acquitted or in connection with any application in
relation to any such proceedings in which relief is under the Act Law granted to him by the Court. During the year, the
Company paid a total of $22,521 in premiums for officers liability insurance.
Proceedings on behalf of company
No person has applied for leave of Court to bring proceedings on behalf of the entity or intervene in any proceedings to
which the entity is a partly for the purpose of taking responsibility on behalf of the entity for all or any part of those
proceedings.
Auditor's independence declaration
The lead auditor's independence declaration in accordance with section 307C of the Corporations Act 2001, for the year
ended 30 June 2021 has been received and can be found on page 6 of the financial report.
Signed in accordance with a resolution of the Board of Directors:
Director: ...............................................................
Ilario Thomas Faenza
Dated this
31st day of August 2021
5
AUDITOR’S INDEPENDENCE DECLARATION
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF BIOME AUSTRALIA LIMITED
ABN: 51 627 364 014
I declare that, to the best of my knowledge and belief, during the year ended 30 June 2021 there have been:
(i)
no contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation
to the audit; and
(ii)
No contraventions of any applicable code of professional conduct in relation to the audit.
JTP ASSURANCE
Chartered Accountants
WAYNE TARRANT
Partner
Signed at Melbourne this 31st August 2021
ABN: 13 488 640 554. Liability limited by a scheme approved under Professional Standards Legislation
6
Biome Australia Limited 2021
ABN 51 627 364 014
Statement of Profit or Loss and Other Comprehensive Income
For the Period Ended 30 June 2021
Note
Sales revenue
Cost of goods sold
5
Gross profit
Other income
Sales and marketing expenses
Corporate and administrative expenses
Occupancy costs
Finance expenses
Depreciation, amortisation and impairments
Other expenses
Loss before income tax
Income tax expense
5
7
7
6
7
8
Loss for the period
Other comprehensive income for the year, net of tax
Total comprehensive loss for the year attributable to the members
2021
2020
$
2,318,402
(1,139,264)
$
866,136
(617,221)
1,179,138
431,423
(3,389,769)
(3,073,540)
(132,617)
(76,109)
(107,294)
(212,348)
248,915
336,221
(1,935,179)
(813,448)
(88,095)
(64,845)
(537,703)
(308,029)
(5,381,116)
-
(3,162,163)
-
(5,381,116)
(3,162,163)
-
-
(5,381,116)
(3,162,163)
The accompanying notes form part of these financial statements.
7
Biome Australia Limited 2021
ABN 51 627 364 014
Statement of Financial Position
As At 30 June 2021
Note
ASSETS
CURRENT ASSETS
Cash and cash equivalents
Trade and other receivables
Inventories
Current tax receivable
Other assets
9
10
11
14
TOTAL CURRENT ASSETS
NON-CURRENT ASSETS
Property, plant and equipment
Intangible assets
12
13
TOTAL NON-CURRENT ASSETS
TOTAL ASSETS
LIABILITIES
CURRENT LIABILITIES
Trade and other payables
Borrowings
Short-term provisions - employee entitlements
Other financial liabilities
15
16
TOTAL CURRENT LIABILITIES
NON-CURRENT LIABILITIES
Borrowings
2021
2020
$
$
609,978
738,214
1,020,895
609
24,634
448,867
276,993
932,475
679
125,437
2,394,330
1,784,451
105,593
-
155,471
6,719
105,593
162,190
2,499,923
1,946,641
705,697
15,735
133,598
83
403,978
16,350
88,594
-
855,113
508,922
64,682
488,183
TOTAL NON-CURRENT LIABILITIES
64,682
488,183
TOTAL LIABILITIES
919,795
997,105
1,580,128
949,536
9,830,488
1,643,175
(9,893,535)
5,877,185
72,500
52,200
(5,052,349)
1,580,128
949,536
16
NET ASSETS
EQUITY
Issued capital
Subscribed share capital
Reserves
Accumulated losses
17
18
TOTAL EQUITY
The accompanying notes form part of these financial statements.
8
Biome Australia Limited 2021
ABN 51 627 364 014
Statement of Changes in Equity
For the Period Ended 30 June 2021
2021
Ordinary
Shares
$
Balance at 1 July 2020
Subscribed Accumulated
share capital
losses
$
$
Option
reserve
Performance
rights
Total
$
$
$
Loss attributable to the members
Shares issued during the year
Share capital raising fees
Issue of share options
Issue of performance rights
Options expired
Performance rights expired
Cancellation of performance rights
Exercise of performance rights
Transfer from subscribed share capital to ordinary shares
5,877,185
3,576,673
(45,870)
350,000
72,500
72,500
(72,500)
(5,052,349)
(5,381,116)
17,400
95,000
427,530
-
52,200
48,405
(17,400)
-
2,432,500
(95,000)
(427,530)
(350,000)
-
949,536
(5,381,116)
3,576,673
(45,870)
48,405
2,432,500
-
Balance at 30 June 2021
9,830,488
-
(9,893,535)
83,205
1,559,970
1,580,128
The accompanying notes form part of these financial statements.
9
Biome Australia Limited 2021
ABN 51 627 364 014
Statement of Changes in Equity
For the Period Ended 30 June 2021
2020
Ordinary
Shares
Subscribed Accumulated
share capital
losses
$
Balance at 1 July 2019
$
$
Option
reserve
Total
$
$
Loss attributable to the members
Shares issued during the year
Share capital raising fees
Cancellation of options
Transfer from subscribed share capital to ordinary shares
2,972,622
3,007,785
(173,222)
70,000
70,000
72,500
(70,000)
(2,011,986)
(3,162,163)
121,800
-
174,000
(121,800)
-
1,204,636
(3,162,163)
3,080,285
(173,222)
-
Balance at 30 June 2020
5,877,185
72,500
(5,052,349)
52,200
949,536
The accompanying notes form part of these financial statements.
10
Biome Australia Limited 2021
ABN 51 627 364 014
Statement of Cash Flows
For the Period Ended 30 June 2021
Note
CASH FLOWS FROM OPERATING ACTIVITIES:
Receipts from customers
Payments to suppliers and employees
R&D tax refund
ATO COVID 19 incentives
Export Market Development Grant
Interest paid
Interest received
2021
2020
$
$
1,893,028
(4,652,432)
179,257
124,000
87,419
(24,812)
406
839,220
(4,363,295)
136,619
166,000
602
(2,393,134)
(3,220,854)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of plant and equipment
Purchase of intangibles
Purchase of property, plant and equipment
39,000
(67,765)
(7,028)
(172,865)
Net cash provided by/(used in) investing activities
(28,765)
(179,893)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issue of shares
Proceeds from borrowings
Repayment of borrowings
Payment of capital raising fees
2,636,292
266,581
(273,993)
(45,870)
3,080,285
462,250
(173,222)
Net cash provided by/(used in) financing activities
2,583,010
3,369,313
Net increase/(decrease) in cash and cash
equivalents held
Cash and cash equivalents at beginning of year
161,111
448,867
(31,434)
480,301
609,978
448,867
Net cash provided by/(used in) operating activities
Cash and cash equivalents at end of financial year
27
9
The accompanying notes form part of these financial statements.
11
Biome Australia Limited 2021
ABN 51 627 364 014
Notes to the Financial Statements
For the Year Ended 30 June 2021
The financial report covers Biome Australia Limited and its controlled entities ('the Group'). Biome Australia Limited and
Controlled Entities is a for-profit Company limited by shares, incorporated and domiciled in Australia.
Each of the entities within the Group prepare their financial statements based on the currency of the primary economic
environment in which the entity operates (functional currency). The consolidated financial statements are presented in
Australian dollars which is the parent entity’s functional and presentation currency.
The financial report was authorised for issue by the Directors on 31 August 2021.
1
Basis of Preparation
The financial statements are general purpose financial statements that have been prepared in accordance with the
Australian Accounting Standards and the Corporations Act 2001.
These financial statements comply with International Financial Reporting Standards as issued by the International
Accounting Standards Board.
2
Going concern
During the financial period ended 30 June 2021 the Group incurred an operating loss of $5,381,116 (2020:
$3,162,163) and a negative cash outflow from operating activities of $2,393,134 (2020: $3,220,854).
The financial statements have been prepared on a going concern basis, which contemplates the continuity of normal
business activity and the realisation of assets and the settlement of liabilities in the normal course of business. The
ability of the Group to continue as a going concern is dependent on securing additional funding through new or existing
investors to fund its operational and marketing activities. These conditions indicate a material uncertainty that may cast
a significant doubt about the entity’s ability to continue as a going concern and, therefore, that it may be unable to
realise its assets and discharge its liabilities in the normal course of business.
The Directors believe that the Group will continue as a going concern. As a result, the financial statements has been
prepared on a going concern basis. However, should the future fundraising be unsuccessful, the entity may not be able
to continue as a going concern. No adjustments have been made relating to the recoverability and classification of
assets and classification of liabilities that might be necessary should the Group not continue as a going concern.
3
Summary of Significant Accounting Policies
(a)
Principles of consolidation
The consolidated financial statements include the financial position and performance of controlled entities from
the date on which control is obtained until the date that control is lost.
Intragroup assets, liabilities, equity, income, expenses and cashflows relating to transactions between entities
in the consolidated entity have been eliminated in full for the purpose of these financial statements.
Appropriate adjustments have been made to a controlled entity’s financial position, performance and cash flows
where the accounting policies used by that entity were different from those adopted by the consolidated entity.
All controlled entities have a June financial year end.
A list of controlled entities is contained in Note 23 to the financial statements.
12
Biome Australia Limited 2021
ABN 51 627 364 014
Notes to the Financial Statements
For the Year Ended 30 June 2021
3
Summary of Significant Accounting Policies (continued)
(b)
Revenue from contracts with customers
The core principle of AASB 15 is that revenue is recognised on a basis that reflects the transfer of promised
goods or services to customers at an amount that reflects the consideration the Group expects to receive in
exchange for those goods or services. Revenue is recognised by applying a five-step model as follows:
1. Identify the contract with the customer
2. Identify the performance obligations
3. Determine the transaction price
4. Allocate the transaction price to the performance obligations
5. Recognise revenue as and when control of the performance obligations is transferred
Generally the timing of the payment for sale of goods and rendering of services corresponds closely to the
timing of satisfaction of the performance obligations, however where there is a difference, it will result in the
recognition of a receivable, contract asset or contract liability.
None of the revenue streams of the Group have any significant financing terms as there is less than 12 months
between receipt of funds and satisfaction of performance obligations.
Specific revenue streams
The revenue recognition policies for the principal revenue streams of the Group are:
Sale of goods
Revenue from the sale of goods is recognised at the point in time when the customer obtains control of the
goods, which is generally at the time of delivery. Revenue is recorded net of returns, rebates and discounts.
Research and development tax incentive grants/Export Market Development Grants
Research and Development tax incentive grants and Export Market Development Grants are recognised when
they are probable of recovery and the amounts can be reliably measured, which presently is in the year when
the claim is received.
Interest
Interest revenue is recognised as interest accrues using the effective interest method. This is a method of
calculating the amortised cost of a financial asset and allocating the interest income over the relevant period
using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through
the expected life of the financial asset to the net carrying amount of the financial asset.
Other revenue
Other revenue is recognised when it is received or when the right to receive payment is established.
13
Biome Australia Limited 2021
ABN 51 627 364 014
Notes to the Financial Statements
For the Year Ended 30 June 2021
3
Summary of Significant Accounting Policies (continued)
(c)
Income Tax
The tax expense recognised in the statement of profit or loss and other comprehensive income comprises
current income tax expense plus deferred tax expense.
Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (loss) for the
year and is measured at the amount expected to be paid to (recovered from) the taxation authorities, using the
tax rates and laws that have been enacted or substantively enacted by the end of the reporting period. Current
tax liabilities (assets) are measured at the amounts expected to be paid to (recovered from) the relevant
taxation authority.
Deferred tax is provided on temporary differences which are determined by comparing the carrying amounts of
tax bases of assets and liabilities to the carrying amounts in the consolidated financial statements.
Deferred tax is not provided for the following:
The initial recognition of an asset or liability in a transaction that is not a business combination and at the
time of the transaction, affects neither accounting profit nor taxable profit (tax loss).
Taxable temporary differences arising on the initial recognition of goodwill.
Temporary differences related to investment in subsidiaries, associates and jointly controlled entities to
the extent that the Group is able to control the timing of the reversal of the temporary differences and it is
probable that they will not reverse in the foreseeable future.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when
the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or
substantively enacted by the end of the reporting period.
Deferred tax assets are recognised for all deductible temporary differences and unused tax losses to the extent
that it is probable that taxable profit will be available against which the deductible temporary differences and
losses can be utilised.
Current and deferred tax is recognised as income or an expense and included in profit or loss for the period
except where the tax arises from a transaction which is recognised in other comprehensive income or equity, in
which case the tax is recognised in other comprehensive income or equity respectively.
Tax consolidation legislation
Biome Australia Limited and Controlled Entities and its wholly-owned Australian subsidiaries have formed an
income tax consolidated group.
Each entity in the tax consolidated group accounts for their own current and deferred tax amounts. These tax
amounts are measured using the ‘stand-alone taxpayer’ approach to allocation.
Current tax liabilities (assets) and deferred tax assets arising from unused tax losses and tax credits in the
subsidiaries are immediately transferred to the parent entity.
14
Biome Australia Limited 2021
ABN 51 627 364 014
Notes to the Financial Statements
For the Year Ended 30 June 2021
3
Summary of Significant Accounting Policies (continued)
(c)
Income Tax (continued)
The tax consolidated group has entered into a tax funding agreement whereby each entity within the group
contributes to the income tax payable by the Group in proportion to their contribution to the Group’s taxable
income. Differences between the amounts of net tax assets and liabilities derecognised and the net amounts
recognised pursuant to the funding agreement are recognised as either a contribution by, or distribution to the
head entity.
(d)
Borrowing costs
Borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset
are capitalised as part of the cost of that asset.
All other borrowing costs are recognised as an expense in the period in which they are incurred.
(e)
Goods and services tax (GST)
Revenue, expenses and assets are recognised net of the amount of goods and services tax (GST), except
where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).
Receivables and payable are stated inclusive of GST.
Cash flows in the statement of cash flows are included on a gross basis and the GST component of cash flows
arising from investing and financing activities which is recoverable from, or payable to, the taxation authority is
classified as operating cash flows.
(f)
Inventories
Inventories are measured at the lower of cost and net realisable value. Cost of inventory is determined using
the first-in-first-out basis and is net of any rebates and discounts received. Net realisable value is estimated
using the most reliable evidence available at the reporting date and inventory is written down through an
obsolescence provision if necessary.
(g)
Property, plant and equipment
Each class of property, plant and equipment is carried at cost or fair value less, where applicable, any
accumulated depreciation and impairment.
Depreciation
Property, plant and equipment, excluding freehold land, is depreciated on a straight-line basis over the assets
useful life to the Group, commencing when the asset is ready for use.
Leased assets and leasehold improvements are amortised over the shorter of either the unexpired period of the
lease or their estimated useful life.
15
Biome Australia Limited 2021
ABN 51 627 364 014
Notes to the Financial Statements
For the Year Ended 30 June 2021
3
Share your feedback
Discover